51
« Last post by flexgustavo on September 04, 2025, 07:15:59 PM »
Hey all,
Just wanted to drop some info and open a discussion about Hydromorphone (aka Dilaudid, or just “D”/“Dillies” on the street). It’s one of the more potent opioids out there, and I’ve noticed it doesn’t get talked about as much as oxy or fent, despite how strong it is.
💊 What is Hydromorphone?
Semi-synthetic opioid
About 5–8x more potent than morphine
Comes in pills, liquid, suppositories, and injectable forms
Commonly used in hospitals for severe pain (post-surgery, cancer, trauma, etc.)
Also available in extended-release (Exalgo) for chronic pain
⚡️ Effects
Strong euphoria and sedation (esp. when IV’d)
Warm body high, nodding, heavy limbs
Fast onset, especially if injected or snorted
Short duration (2–4 hrs IR), which can lead to frequent redosing
Some people describe it as “cleaner” than morphine with less histamine release/itching, but that varies a lot by person.
⚠️ Risks / Warnings
High overdose potential, especially for opioid-naive users
Respiratory depression is real—especially if mixed with benzos, alcohol, or other CNS depressants
Very addictive; tolerance builds quickly
IV use adds risks of abscesses, collapsed veins, infections, etc.
Withdrawal is similar to other strong opioids—cold sweats, anxiety, RLS, insomnia, GI issues, etc.
🧠 Harm Reduction Tips
Start low, especially if you’re used to weaker opioids (like codeine or oxy)
Avoid mixing with depressants (alcohol, benzos, GHB, etc.)
Have naloxone (Narcan) around—especially if you’re using alone
Know your source if you’re getting it off-script. Fakes laced with fent or iso are out there
If you’re IV’ing it, use clean rigs, sterile water, and rotate injection sites
💬 Curious What Others Think:
Have you used hydromorphone medically or recreationally? How did it compare to other opioids for you?
Anyone have experience with Exalgo (ER version)? Worth it or nah?
Ever microdosed it for pain or mood management?
Would love to hear your stories, thoughts, warnings, or advice. Let’s keep it safe and respectful—especially since we’re dealing with heavy stuff here.
Peace and stay safe out there. ✌️
52
« Last post by smfadmin on August 29, 2025, 09:26:44 AM »
🧠 Dopamine & MA + Piperine / Hordenine Stack — Condensed Notes
1. Piperine + Dopamine Receptors
💊 Piperine **does NOT directly increase dopamine receptor sensitivity**
⚡ Main effect: **CYP3A4/CYP2D6 inhibition**, slows MA metabolism → higher, longer dopamine
🧪 Mild **MAO inhibition** possible
⚠️ High doses (200 mg+) → gut irritation, unpredictable effects
2. Effects of MA + Piperine
⏳ Slower onset, **sharper peak once absorbed**
📈 **Extended plateau** → longer functional stimulation
❌ Piperine increases exposure, **does not restore receptor sensitivity**
3. Hordenine + MA + Piperine
🌿 Hordenine: **NRI + mild TAAR1 activity**, additive with MA
⏱ Piperine slows Hordenine clearance → stronger effect
💥 Combined: higher norepinephrine + dopamine, longer duration, elevated HR/BP
⚠️ Not a resensitizer — stresses desensitized receptors
4. Timeline of Effects (150 mg MA + 200 mg Piperine + 450 mg Hordenine)
| Time | Effect |
|------------|--------|
| 0–0.5 hr | Mild alertness, delayed onset |
| 0.5–2 hr | Rising phase; jitters, mild jaw tension |
| 2–6 hr | Peak/plateau; functional stimulation, motivation, cardiovascular load |
| 6–12 hr | Declining; wired tail, restlessness, appetite suppression, sleep disruption |
| 12–24 hr | Comedown; fatigue, low mood, mental fog, gut irritation |
5. Dopamine Receptor Resensitization
🔹 High MA tolerance → D1/D2 downregulation
🔹 Recovery = **rest receptors, not more dopamine**
Recovery Protocol (60 × 1000 mg CDP-Choline)
💊 Core Stack:
- CDP-Choline: 250–500 mg AM with food/fat
- Omega-3 (DHA/EPA): 1000–2000 mg/day
- Magnesium glycinate/threonate: 200–400 mg PM
🧩 Optional Builders:
- Uridine Monophosphate: 150–250 mg AM
- NAC: 600–1200 mg/day
- B-vitamins: B6, B9, B12
🏃 Lifestyle:
- Exercise 3–5×/week → boosts D2 receptor density
- Solid sleep → receptor density rebounds
- Novelty/learning → natural dopamine stimulation
⏱ Timeline:
- 1–2 weeks → subtle clarity/focus
- 1–2 months → reward sensitivity improves
- 3+ months → motivation rebound
- 3–6 months → major receptor recovery (if MA minimal)
⚠️ MA Use During Recovery:
- Low-dose or spaced out only
- Micro-dosing occasionally okay, frequent use slows recovery
6. CDP-Choline Notes
- Supports **receptor density, synapse repair, membrane health**
- Works best with **DHA + uridine**
- Dose: 250–500 mg/day, split 1000 mg capsules
- Benefits over **weeks–months**
- Supply: 60 × 1000 mg → ~4 months at 500 mg/day
7. Safety & Warnings
- MA + Piperine + Hordenine → increased cardiovascular load; monitor HR/BP
- Piperine prolongs clearance → longer effects
- Gut irritation, restlessness, insomnia possible
- Stack **does NOT resensitize receptors**; repeated use worsens tolerance
8. TL;DR
- ⚡ Piperine = metabolic amplifier, not receptor fixer
- 🧠 CDP-Choline + DHA + uridine + magnesium + lifestyle = true receptor rebuilding
- 🚀 MA/Hordenine/Piperine = functional boost, long tail, receptor stress
- 🔑 Recovery = **time off stimulants + nutrition + exercise + sleep**
53
« Last post by smfadmin on August 25, 2025, 10:55:55 PM »
https://www.psychiatrist.com/news/songs-that-shape-our-memories/?utm_source=Klaviyo&utm_medium=email&utm_campaign=news_weekly&klid=01HYSTTNXNB74YAYKT9XMYQCN0&_kx=va3uRF3O8-7Dg_zjrKMZJk0wdery-TOTVyZ3l8muM1g.VpkqxCSongs That Shape Our MemoriesAugust 21, 2025 Clinical relevance: Songs don’t just trigger memories. They can determine which ones spring to mind and how powerful they are. A large new study shows that a song’s acoustic features influence which memories surface and how strongly they resonate. High-energy tracks tend to spark fast, social memories, while acoustic songs evoke slower, more deeply personal recollections. The findings could guide therapies n by tailoring playlists to patient needs. For most of us, a familiar song can be a time machine. It can instantly take us back to our first kiss, an early heartbreak, or an unforgettable road trip. Now, new research from Goldsmiths, University of London, shows that the sound of a song can help shape which memory pops up. They can even influence how hard those memories hit. The study, published in PLOS One, is the largest so far to directly tie the acoustic features of music to the qualities of music-evoked autobiographical memories (MEAMs). And the results could determine therapies for a host of mental health issues, such as dementia and depression. It can also shed new light on how memory and music interact. A Large-Scale Look at Musical Memory: Psychologists Safiyyah Nawaz and Diana Omigie recruited 233 adults, between the ages of 18 and 76, to participate in their online experiment. The researchers asked each participant to pick a song that meant something to them and describe the memory associated with it. They also rated the memory’s vividness, importance, and emotional tone. Later, they listened to 10 short clips of songs culled from the Billboard Hot 100 charts during their formative years (ages 9 to 19, a crucial time for music-related memories). If a song sparked something, participants again rated the recall for detail and emotional content. Throughout the study, participants provided more than 1,400 music-evoked memories. It was enough to allow the researchers to analyze not only what people remembered, but why certain songs wield such power. Using Spotify’s Web API, the team managed to isolate nine auditory features from each memory-evoking track, including energy, loudness, acousticness, tempo, and danceability. A subsequent statistical analysis revealed a single critical factor, which the researchers dubbed energeticness-acousticness (E-A). One end of the spectrum featured energetic, loud, electronic or dance-oriented songs. And the other? Quieter, more acoustic tracks. Different Sounds Mean Different Memories: The contrast between high-energy and acoustic songs mapped neatly onto differences in the types of memories they brought forth: High-energy songs (like club tracks or pop anthems) tended to elicit memories marked by excitement, amusement, and social interaction. Listeners typically associated these songs to concerts, parties, or some other group event. Lower-energy, more acoustic tracks (like ballads or classical compositions) seemed to be more likely to elicit memories that the participants described as vivid, unique, and personally important. Listeners associated these emotional tunes to a sense of calmness, sadness, romance, or aesthetic appreciation. Notably, acoustic songs often evoked memories brimming with more negative emotion words. Even so, the participants still rated these recollections as overall positive experiences. That paradox, the authors point out, underscores music’s ability to reframe painful events in a more forgiving light. The researchers also looked at how quickly – and vividly – memories surfaced. Participants recalled energetic songs (and the memories tied to them) more quickly and more often. While acoustic tracks prompted slower recall but produced longer, more detailed memory descriptions. Simply put, upbeat music performed better when triggering many memories, but quieter music tended to yield more powerful ones. One striking difference emerged between self-selected songs and experimenter-chosen chart hits. Listeners consistently rated memories tied to personally chosen songs as more vivid, emotional, unique, and important. They also contained more specific sensory details. This, the authors suggest, hints that while the acoustic profile of a song matters, a personal connection might matter even more. Why This Matters: The findings carry implications for both psychology and clinical practice. Dementia caregivers are already using music-based reminiscence therapy to spark forgotten episodes and strengthen identity. Knowing which song types are most likely to evoke vivid or social memories could help therapists tailor playlists to patient needs. For example, upbeat, high-energy songs might be useful for encouraging social engagement, while acoustic ballads could help surface personally meaningful life stories. The study also emphasizes the need to move beyond simple “positive versus negative” emotional models. By tracking specific categories like romance, aesthetic appreciation, or amusement, the researchers make a case that music can cue up a far richer emotional palette than earlier two-dimensional models of arousal and valence suggested.
54
« Last post by smfadmin on August 10, 2025, 01:01:38 PM »
Don’t fully trust your friends. Sometimes, you learn more from those who disagree with you.
Speak less than needed. Silence often says more than words.
Don’t try to look perfect all the time. People get jealous or suspicious.
Learn when to act and when to wait. Timing matters.
Show your worth through what you do, not by arguing.
Know when to stop. Winning too much can backfire.
Don’t cut yourself off from everyone. Being alone too much is risky.
Sometimes stepping away makes people value you more.
Focus your energy on one goal instead of spreading it thin.
Think your own way, but blend in when needed.
55
« Last post by smfadmin on August 08, 2025, 06:08:56 AM »
https://www.livescience.com/space/mars/nasa-finds-multi-billion-year-old-coral-on-mars?utm_medium=referral&utm_source=pushly&utm_campaign=Space%20Audience8 Aug, 2025 NASA's Curiosity rover has snapped black and white images of a rock on the Martian surface that looks remarkably like a piece of coral. The strange object is in fact a small, light-colored, wind-eroded rock, which the rover found inside the Red Planet's Gale Crater on July 24 — but it looks remarkably similar to the reef-building creatures found in Earth's oceans. A black and white picture taken with Curiosity's Remote Micro Imager — a high-resolution, telescopic camera that is mounted on the rover — and shared by NASA in a statement on Aug. 4 shows the approximately 1-inch-wide (2.5 centimeters) rock with its intricate branches. "Curiosity has found many rocks like this one, which were formed by ancient water combined with billions of years of sandblasting by the wind," NASA representatives wrote in the statement. Coral-shaped rocks on Mars started forming billions of years ago, when the Red Planet still had water, according to the statement. Just like water on Earth, this water was full of dissolved minerals. It percolated through small cracks in Martian rocks, gradually depositing minerals and forming solid "veins" inside the rocks. These veins form the strange branches of the coral-shaped object that we see in Curiosity's picture today, after millions of years of erosion by sand-laden winds wore away the rock. The article continues at the source link ... The Curiosity rover discovered what looks like coral on Mars. (Image credit: NASA Jet Propulsion Laboratory):
56
« Last post by Chip on August 07, 2025, 08:25:20 AM »
That's excellent news Mr Pooper, that you're mobile again; sadly, I have lost my license for 3 years so I get it so you have more reasons to smile about now. I ran your reply through AI again and this is the reply: 🧪 Ongoing Fentanyl Positives Despite Abstinence – Full Case & Update“I’ve been clean for almost a year, yet my clinic keeps saying I’m positive for fentanyl. Dipsticks and home tests are negative, but the lab says positive. My credibility is being destroyed.”--- 🚨 Summary of the Issue- Stopped using fentanyl and meth in September
- Multiple random fentanyl positives despite months of clean results in between
- Methadone given in dissolvable disc pills, sometimes handled without gloves
- Environmental contamination suspected
- Now a pattern: dipstick test = negative, lab test = positive
--- 📅 Update from Patient“So a little update. I’m STILL getting positives for fentanyl at my methadone clinic. They do a dipstick test before sending the urine sample to the lab. It’s tested NEGATIVE every time with the dipstick test. But once sent to the lab, they are claiming it’s detected POSITIVE for fentanyl.
I’ve even gone as far as to do my own at-home fentanyl urine test, and they test NEGATIVE every time. I even got fentanyl test wipes to test surfaces for fentanyl.
It seems like I’ll get a few dirty tests, then one clean. Few dirty tests, then one clean.
My clinic is flat-out accusing me of using. They claim it’s impossible to have this many false positives. I asked if anyone else was having similar issues — they said no. They occasionally have false positives, but not 5+ like me.
I’m really upset by this. Being accused of using, despite being clean for almost a year, is a horrible feeling. And now with the added urine tests claiming positive drug use, my credibility is shot, and it’s making me untrustworthy.”
--- 🧪 1. Possible Explanations🔹 A. Environmental Contamination Possible, though rare. Fentanyl can transfer via skin oils if staff handle contaminated items and then handle medication. One contaminated pill could cause a positive. 🔹 B. Ultra-Sensitive Lab Testing Labs may use cutoffs as low as 1–2 ng/mL, so even microscopic contamination can trigger a positive. This could explain why dipsticks (less sensitive) are negative but lab results are positive. 🔹 C. Stored in Fat Tissue? Unlikely given the random pattern and long gaps between use and positives. 🔹 D. False Positives at the Lab Uncommon for fentanyl, but possible with lab error, cross-contamination, or issues in sample handling. --- 🧾 2. Steps to Prove Cleanliness✅ A. Request GC/MS or LC-MS/MS Confirmation These tests can: - Differentiate fentanyl from analogues
- Show exact nanogram level
- Confirm if metabolites are present (proves ingestion)
Say: “Can I have every positive urine sample sent for GC/MS confirmation before any action is taken?”✅ B. Independent Testing On the same day as your clinic test: - Do an independent lab urine test
- Do a hair follicle test for 90-day history
✅ C. Document Everything Track: - Every clinic test result
- Every independent test result
- Handling conditions of methadone
✅ D. Evidence of Pill Handling Practices Note glove use, packaging methods, and storage conditions. Consider requesting a change to liquid methadone or blister packs. --- 🛡️ 3. What to Say to the Clinic
“I’ve been clean since September. My clinic dipstick tests are always negative, and my at-home tests are negative, yet the lab reports positives. This suggests there is either contamination or lab error.
I am not accusing anyone of misconduct, but I am asking for GC/MS confirmatory testing on all positives, and I’d like to explore ways to avoid any possible contamination in handling or packaging of my doses.”
--- 👩⚖️ 4. If the Clinic Refuses to Cooperate- File a written request for confirmatory testing
- Contact your state’s Patient Advocate or Ombudsman
- Consider a clinic transfer
--- 🧷 TL;DR Action Plan✅ Request GC/MS confirmation on all positives ✅ Get independent lab + hair tests same day as clinic ✅ Keep detailed documentation log ✅ Request sealed or liquid doses to avoid contamination risk ✅ Stay professional, polite, and persistent --- 💬 Final Note Intermittent positives with all on-site and home tests being negative point toward either environmental contamination or lab processing issues. Without GC/MS confirmation, it’s impossible to know which — but persistence and independent verification can protect your credibility. (AI reply finished)@Mr.pooper, tell them if you were using Fentanyl (and its stored in your fatty tissue for a while) then you'd have ALL tests positive and you'd be in opi withdrawal on the negative days and need more Methadone (which you do not as I assume that you're stable now). Any chance of changing clinics or getting a GC/MS or a hair follicle test ?
57
« Last post by Mr.pooper on August 06, 2025, 11:45:01 PM »
So a little update. Im STILL getting positives for fentanyl at my methadone clinic….they do a dipstick test before sending the urine sample to the lab. Its tested NEGATIVE every time with the dip stick test. But once sent to the lab, they are claiming its detected POSITIVE for fentany.
ive even gone as far to do my own in home fentanyl urine test, and they test NEGATIVE every time. I even got fentanyl test wipes to wipe down things in my environment to test surfaces for fentanyl.
It seems like ill get a few dirty tests. Then one clean. Few dirty tests. Then one clean.
My clinic is flat out just accusing me of using. Claiming it’s impossible to have this many false positives
I asked if anyone else was having similar issues, and they said no. They occasionally have false positives, but not 5+
Im really upset by this. Being accused of using, despite being clean for almost a year is a horrible feeling. And now with the added urine tests claiming positive drug use, my credibility is shot, and making me untrustworthy.
On a positive note, I managed to get my drivers license and purchased a 2016 suv. I had to work hard to get that drivers license too! I had to take the written test and do a on road driving test like when i was a teenager..i never thought id ever legally be able to drive again, or own a car ever again. So im really proud to have ID and a car w/ legal papers. I also just got my new teeth! The dentist instructed me to smile and look at them in a mirror, and I realized i didnt know how to smile anymore. Ive been sad for so long, and on top of missing most my teeth, i never smile anymore. To the point i dont even have the facial muscles to do it anymore.
58
« Last post by smfadmin on August 06, 2025, 03:17:29 PM »
https://www.wired.com/story/psychedelic-therapy-mdma-maha/?utm_source=nl&utm_brand=wired&utm_mailing=WIR_BigStory_080325&utm_campaign=aud-dev&utm_medium=email&utm_content=WIR_BigStory_080325&bxid=67883001cdeb6340250c3d97&cndid=85787720&hasha=c9edd795ab58c731e64cc2832451a46d&hashb=92cd5a4e4f9a554757364e6cc6a52d8ff33f14ec&hashc=1e7f7a9239bb44f191dc979b8fe5e634e587dfe020b84a653d2040468a8b342b&esrc=bx_multi2nd_science&utm_term=WIR_BigStoryPsychedelic Therapy Crashed and Burned. MAHA Might Bring It BackJul 29, 2025 Abuse allegations and infighting helped kill a campaign to legalize MDMA for medical use. Trumpworld is giving the therapy’s advocates hope for a second shot. This was supposed to be the year of the MDMA revolution. About this time last year, prescription MDMA looked like a sure thing. After decades of clinical research, political wrangling, and aggressive promotion, the popular underground club drug was set to be tamed and medicalized, with a stamp of approval from the US Food and Drug Administration. Then, it wasn’t. In a stark change of course, the FDA rejected the MDMA therapy it had been considering by a 10-1 vote. The decision derailed psychedelic medicine for the foreseeable future. Except for one thing—an unexpected lifeline from the Trump administration. In May, the FDA’s new commissioner, surgical oncologist Marty Makary, appeared on cable news to declare MDMA and other Schedule 1 narcotics “a top priority for this FDA and this administration.” Elsewhere, Mr. MAHA himself, the US Health and Human Services secretary, Robert F. Kennedy Jr., has spoken positively about the psychoactive stems-and-bark tea ayahuasca. Matt Zorn, a lawyer recently appointed to RFK Jr.’s department, had previously fought the US government to allow access to cannabis and psychedelic mushrooms. Casey Means, Trump’s nominee for surgeon general, has spoken of the benefits of psilocybin-assisted therapy, claiming that psychedelic mushrooms helped her find love and made her feel like “part of an infinite and unbroken series of cosmic nesting dolls.” Psychedelic medicine, as it turns out, slots rather comfortably into the burn-it-all ethos of RFK Jr.’s movement. But as MDMA’s advocates regroup to take advantage of this surge of support, they’re also reckoning with why they failed to win over the FDA—and whether a second attempt could go better. Could the psychedelic world’s new Trumpworld allies be the ones who finally help it achieve its goal?   MDMA-Web-TT-3.webp (80.68 kB . 1280x1639 - viewed 159 times)For almost half a century, American psychedelic medicine—and MDMA in particular—has had one indispensable advocate: Rick Doblin. On a cool December morning, I met Doblin at his bright purple craftsman home in the Boston suburbs. Dressed in a well-worn chamois shirt and khakis and with a wiry tangle of hair, he was cheery and avuncular. His look was classic New England and a bit bedraggled, befitting the scion of a wealthy industrialist family turned elder statesman of the counterculture. Doblin first tried LSD in 1971 as a freshman studying psychology at Florida’s experimental New College. By 1982, he was studying under pioneering psychedelics researcher and therapist Stanislav Grof at the Esalen Institute in Big Sur, California. At the time, many at Esalen were excited about a legal chemical called MDMA, which was said to help people conquer fear and forge profound connections with others. Doblin sampled the drug with a girlfriend and was shocked at how easy it became to talk through their issues. But then, to Doblin’s chagrin, the US criminalized MDMA, and in 1986 he founded a nonprofit called MAPS—the Multidisciplinary Association for Psychedelic Studies. For the next several years, MAPS was a one-man operation. To advocate for MDMA’s legalization, Doblin collected reports from animal studies on the drug’s toxicity and lined up experts to argue with Drug Enforcement Administration officials on Phil Donahue. He slipped into Nicaragua during its civil war and provided the drug to clinicians to treat traumatized soldiers and civilians. He even subjected himself to excruciating spinal taps in an attempt to disprove a prevalent belief that MDMA depleted natural stores of serotonin. Doblin believed early on that it was essential to distance MAPS from the counterculture to gain mainstream credibility. (The organization’s first Psychedelic Science conference in 2010 instituted a “no tie-dye” rule for staff.) He set out to collect clinical evidence on the benefits of MDMA and other prohibited drugs. He then used those results to wage a campaign to change public opinion and ultimately end prohibitions. Between 2005 and 2017, MAPS refined a model for clinicians to administer MDMA to patients suffering from post-traumatic stress disorder, guide their experiences, and provide post-trip emotional support. Its 74-page manual stressed the importance of “inner healing intelligence”—a concept touted by Doblin’s mentor Grof, which holds that the human psyche has an “innate capacity” to heal itself. During this time, MAPS operated as a charity, taking in over $6.7 million in 2013 to fund its research and advocacy. The organization prided itself on living its values of drug destigmatization; it had a policy where employees could consult with their managers on “smokable tasks” that could be completed under the influence of drugs. (“I personally feel like strategizing and brainstorming goes better when I’m high,” Doblin explains.) But the cornerstone of Doblin’s plan—establishing MDMA’s efficacy in a clinical trial—required resources of a different magnitude. MAPS needed to raise more than $100 million for research and operational costs. So in 2014 the organization minted a for-profit subsidiary, which came to be known as Lykos Therapeutics. The article continues at the link above ... Photograph: Tonje Thilesen:
59
« Last post by smfadmin on August 06, 2025, 06:47:29 AM »
PEA + Hordenine Quick Guide
Why combine them?
- Phenethylamine (PEA): Quick mood lift & energy boost, but broken down fast by MAO-B.
- Hordenine: Mild stimulant & reversible MAO-B inhibitor, extends and strengthens PEA's effects.
Basic Protocol
1. Take Hordenine 50–100 mg orally, 15–20 min before PEA.
2. Take PEA 250–500 mg (can go higher if tolerated) once hordenine lead-in is complete.
3. Optional booster: Half your PEA dose 45–60 min later, without extra hordenine.
3-Day Bare-Bones Cycle
- Day 1 (Strong): Hordenine 75–100 mg + PEA 500–800 mg (split optional).
- Day 2 (Moderate): Hordenine 50–75 mg + PEA 300–500 mg.
- Day 3 (Light): Hordenine 50 mg + PEA 250–400 mg.
Then take 1–2 days off before repeating.
Onset Timeline
- 0–10 min: Subtle mental clarity.
- 10–20 min: Mood lift, energy, talkativeness.
- 20–45 min: Plateau.
- 45–60+ min: Fade or drop-off.
Tips
- Empty stomach = faster onset, but higher risk of GI upset.
- Take with a small snack to reduce diarrhea risk.
- Avoid stacking with strong stimulants to reduce BP/HR spikes.
Cautions
- Avoid if on MAOIs, SSRIs, SNRIs, or with certain health conditions.
- Monitor blood pressure and heart rate.
- Keep hordenine under ~200 mg/day.
Based on personal experience and high tolerance stimulant use scenario.
60
« Last post by smfadmin on July 22, 2025, 05:49:31 PM »
Natural Compound Found in Magic Mushrooms Delays Aging and Extends Lifespan, Study Suggests https://share.google/Jjmcpg80GdgBKcOMjNatural Compound Found in Magic Mushrooms Delays Aging and Extends Lifespan, Study SuggestsJuly 21, 2025  Clock-Aging-Time-Old-1536x1024.jpg (165.55 kB . 1536x1024 - viewed 155 times)In a surprising breakthrough in aging science, Emory University researchers have found that psilocin, a compound derived from psychedelic mushrooms, significantly extends the lifespan of human cells and elderly mice. Credit: Stock Psilocybin improved longevity and health markers in mice and cells. The findings reveal unexpected systemic benefitsAs the anti-aging industry, fueled by optimism and a flood of supplements, generated more than $500 million in revenue last year, scientists at Emory University discovered a compound that directly slows aging in both cells and living organisms. In a new study published in Nature Partner Journals’ Aging, researchers show that psilocin, a metabolite formed when psilocybin (the psychoactive compound in psychedelic mushrooms) is consumed, increased the lifespan of human skin and lung cells by over 50%. Mouse trials reveal improved survival and appearance At the same time, researchers carried out the first long-term in vivo study to assess how psilocybin affects the entire body in aged mice. The study used 19-month-old mice, which correspond to humans aged 60 to 65. Mice that received an initial low dose of 5 mg psilocybin followed by a monthly 15 mg dose over a 10-month period showed a 30% higher survival rate compared to untreated controls. These treated mice also exhibited healthier physical traits, including better fur condition, reduced white hair, and evidence of hair regrowth. Although psilocybin is most commonly studied for its psychological effects, this research indicates that it also targets several key biological markers of aging. The compound appears to reduce oxidative stress, enhance DNA repair mechanisms, and maintain telomere length. Telomeres are protective structures at the ends of chromosomes that guard against damage and are closely linked to the development of age-associated diseases such as cancer, neurodegeneration, and cardiovascular disorders. These underlying cellular processes play a critical role in both aging and disease onset. Based on these findings, the study suggests that psilocybin holds promise as a groundbreaking approach to anti-aging therapies and may offer meaningful benefits for aging populations. “Most cells in the body express serotonin receptors, and this study opens a new frontier for how psilocybin could influence systemic aging processes, particularly when administered later in life,” says Louise Hecker, PhD, senior author of the study and former associate professor at Emory University, where the work began and was funded. While psilocybin is often associated with its effects on the brain, its broader physiological impacts remain largely unexplored. Despite its reputation for inducing hallucinations, the compound acts on serotonin receptors, which are found throughout the body. Late-life interventions still show benefit: “Our study opens new questions about what long-term treatments can do. Additionally, even when the intervention is initiated late in life in mice, it still leads to improved survival, which is clinically relevant in healthy aging,” adds Hecker, currently an associate professor at Baylor College of Medicine. This news comes on the heels of KFF’s recent report that U.S. life expectancy is still below that of other countries similar in income and size, with an average lifespan of 78.4 years, compared to 82.5 years elsewhere. Not only was it the lowest, but as the lifespan in similar countries increased by 7.9 years from 1980-2022, whereas the U.S. life expectancy has only increased by 4.7 years. Improved aging, not just longer life: “This study provides strong preclinical evidence that psilocybin may contribute to healthier aging– not just a longer lifespan, but a better quality of life in later years,” says Director of Psychedelic Research at Emory University’s Department of Psychiatry Ali John Zarrabi, MD. “As a palliative care physician-scientist, one of my biggest concerns is prolonging life at the cost of dignity and function. But these mice weren’t just surviving longer—they experienced better aging,” adds Zarrabi, co-investigator of the study. Zarrabi emphasized the importance of further research in older adults, as well as the well-documented overlap between physical and mental health. “Emory is actively involved in Phase II and III clinical trials of psilocybin-assisted therapy for depression, and these results suggest we also need to understand psilocybin’s systemic effects in aging populations,” says Zarrabi. * “My hope is also that if psilocybin-assisted therapy is approved as an intervention for depression by the FDA in 2027, then having a better quality of life would also translate into a longer, healthier life.”
|
Recent Posts
